Skip to content
Sign in
Artwork for Charged Alpha Stock Encyclopedia
BusinessInvesting

Charged Alpha Stock Encyclopedia

Colton Thomas

⚡ Charged Alpha — The S&P 500 Stock Encyclopedia Data-driven deep dives into every stock in the S&P 500 after every earnings report. Each episode breaks down one company from open to close: what they do, how the numbers look, what Wall Street thinks, the bull case, the bear case. 🛠️ Check out our free beginner-friendly screening tools for stocks, ETFs, options, crypto, bonds, REITs & more at https://chargedalpha.com — no signup, no paywall. 📊 What you get in every episode: Company overview & competitive moat Full financial breakdown — valuation, revenue, margins, cash flow Analyst consensus & price targets Bull case vs. bear case Peer comparison, options flow & insider activity Key metrics to watch ⚠️ Not financial advice. For educational purposes only. Episodes are researched, written, and produced using AI-assisted tools. All data aggregated from publicly available sources. #stocks #investing #S&P500 #stockanalysis #chargedalpha #financialdata #earningsreport #earnings

Play
Open in
  • 193 episodes
  • Avg 14 min
  • English

Episodes 193

NewestOldestLongest
All20Unplayed20In progress0Played0
Counted on this page — what you have heard stays on this device, so it is not something the list can be paged by.
  • Yesterday · 12 min

    KBH Stock: Backlog Grew, Demand Slowed — Q3 FY2026

    KB Home (KBH) Q3 FY2026 — Reference price $48.59 from the saved September 22 quote; a post-print reaction is not verified. Backlog grew, but demand per community weakened. KB Home’s sequential margin recovery meets rising net debt and a book value dominated by inventory. THE CALL: HOLD (3/5, MODERATE) — base-case value ~$50.00 vs ~$48.59 today. KEY METRICS: - Revenue $1,297.101M, down 19.96% YoY - GAAP diluted EPS $1.05 versus $1.61 - Net orders 2,604, down 11.73% - Monthly orders per community 3.1 versus 3.8 - Backlog 4,398 homes, up 1.50% YoY but down 2.83% sequentially - Housing gross margin 16.5%; adjusted 16.8% - Defined net debt $1,950.127M, up $485.764M from fiscal year-end - Book value $62.56 per share; base fair value $50 What to watch: Orders per community ≥3.5, housing gross margin ≥16.6% without larger charges, leverage stabilizing and verified cash improvement; reconsider near $40 only with fundamentals intact. Full research packet: https://chargedalpha.com/research/kbh-q3-fy2026 Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

  • Yesterday · 13 min

    AZO Stock: The Margin Rebound Has a Refund Inside — Q4 FY2026

    AutoZone, Inc. (AZO) Q4 FY2026 — The reference is the September 21 close of $2,803.25, before this earnings release; no verified post-print move is asserted. AutoZone’s gross margin rebounded, but tariff refunds and the comparative LIFO benefit explain more than the entire improvement. Commercial growth remains strong while inventory and investment absorb cash. THE CALL: HOLD (3/5, MODERATE) — base-case value ~$2800.00 vs ~$2803.25 at the September 21 pre-release close. KEY METRICS: - Q4 revenue $6,594.879M, up 5.64% - GAAP diluted EPS $56.05 versus $48.71 - Gross margin +182 bp includes tariff +145 bp and LIFO comparison +105 bp - FY2026 operating cash $3,302.846M less capex $1,496.255M = FCF $1,806.591M - Inventory grew 10.1%; domestic same-store sales grew 1.6% What to watch: Domestic same-store sales above 3%, commercial weekly sales per program above $19K, and inventory growth converging toward sales; review by December 31, 2026. Full research packet: https://chargedalpha.com/research/azo-q4-fy2026 Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

  • Yesterday · 13 min

    THO Stock: A $100M Savings Promise Meets a Cash-Flow Reset — Q4 FY2026

    THOR Industries (THO) Q4 FY2026 — The valuation uses the September 21 pre-print close of $69.94; no post-print reaction is asserted. THOR promises over $100M of annual earnings improvement once its initiatives are fully implemented. Meanwhile, FY2026 free cash flow fell to $168.8M and dividends plus buybacks ran ahead of it. Can the savings become cash without a retail rebound? THE CALL: HOLD (3/5, MODERATE) — base-case value ~$70.00 vs ~$69.94 at the September 21 pre-print close. KEY METRICS: - Q4 revenue $2,311.628M, down 8.4% YoY - Q4 gross margin 12.4%, down 230 bps - Q4 diluted EPS $0.78 vs $2.36 - FY2026 FCF $168.836M = OCF $321.223M less capex $152.387M - July 31 gross debt less cash $393.780M - Ultimate $100M+ annual earnings improvement has unquantified timing What to watch: North American gross margin above 10%, FCF trajectory toward $250M+, and a dated net-savings bridge. Full research packet: https://chargedalpha.com/research/tho-q4-fy2026 Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

  • Monday · 13 min

    ANAB Stock: $5.11 EPS Is the Wrong Headline — AnaptysBio Q2 2026

    AnaptysBio, Inc. (ANAB) Q2 2026 — September 21 close $54.99, down 0.39%; the release-session label is unverified, so this is not necessarily a clean post-print reaction baseline. Anaptys reported $5.11 of Q2 diluted EPS, but a $181.491M tax benefit drove the profit. The real value remains the post-Sagard Jemperli royalty stream, under an agreement now in unresolved litigation. THE CALL: HOLD (3/5, MODERATE) — base-case value ~$58.00 vs ~$54.99 today. KEY METRICS: - Q2 collaboration revenue $27.488M, +23.5% YoY - H1 Jemperli global sales $644.1M, +30.3% YoY - Q2 pretax loss $4.174M before $181.491M tax benefit - June cash + investments $164.143M - Sagard earned about $302.5M through June - GSK/Tesaro hearing scheduled October 20, 2026 - HOLD 3/5; $58 base / $55.50 weighted / $25–$95 scenarios What to watch: Read the actual litigation order, grade AZUR-1 and Quimilza decisions, and track Sagard paydown against H2 2027. Full research packet: https://chargedalpha.com/research/anab-q2-2026 Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

  • Monday · 9 min

    ABVX Stock: The Runway Is Funded. Can Obefazimod Earn It? — Q2 2026

    Abivax S.A. (ABVX) Q2 2026 — September 21 saved close $103.45, down 1.51% from $105.04. SEC acceptance metadata and the issuer release dateline conflict, so no reaction baseline is claimed. Abivax now has funding into Q4 2029 and a planned obefazimod NDA, but nearly $8.6B of diluted value above capital leaves little room for execution mistakes. THE CALL: HOLD (3/5, MEDIUM) — base-case value ~$110.00 vs ~$103.45 today. KEY METRICS: - Q2 net loss €117.433M; H1 operating outflow €102.509M - June liquidity €402.4M; July net proceeds €767.1M - Management runway into Q4 2029 - Post-offer ordinary shares 87.177M; diluted 95.449M - Planned UC NDA by end-2026; Crohn’s topline mid-2027 - HOLD 3/5; $110 base / $112.50 weighted / $45–$185 cases What to watch: Submit the UC NDA by year-end, maintain the Q4 2029 runway, control burn, deliver mid-2027 Crohn’s data and explicitly remediate the internal-control weaknesses. Full research packet: https://chargedalpha.com/research/abvx-q2-2026 Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

  • Thursday · 12 min

    IPHA Stock: $75M Buys Time, Not Approval — Innate Pharma H1 2026

    Innate Pharma S.A. (IPHA) H1 2026 — September 17 intraday quote $1.855 at 11:50 a.m. EDT, down 7.71% from the $2.01 previous close. Not the final session close. Innate Pharma closed the Sobi partnership and an equity financing, extending the expected runway. The cash has claims, the shares have new owners, and clinical evidence still determines the value. THE CALL: HOLD (2/5, LOW) — base-case value ~$1.80 vs ~$1.855 today. KEY METRICS: - H1 combined income €5.663M; licensing €3.115M - IFRS net loss €19.623M; operating outflow €21.044M - Sobi $75M upfront triggered; receipt expected - Equity raise €30M gross / €27.6M estimated net - Post-placement ordinary shares 111.719M; fully diluted 117.822M - HOLD 2/5; $1.80 base / $1.75 weighted / $0.40–$4.00 scenarios What to watch: Confirm the $75M receipt, inspect PACIFIC-9 and IPH4502 data, dose the first TELLOMAK-3 patient by Q1 2027, and track burn plus dilution. Full research packet: https://chargedalpha.com/research/ipha-h1-2026 Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

  • Thursday · 13 min

    IMMR Stock: Profit Recovered. What Is Recurring? — Q1 FY2027

    Immersion Corporation (IMMR) Q1 FY2027 — FMP September 16 regular close $7.12; financial anchor July 31 and latest common count September 8. Post-release dated observation, not a live quote. Immersion returned to parent-attributable profit, but investment gains did much of the work. We separate recurring haptic economics, BNED minority ownership and claims against the parent cash balance. THE CALL: HOLD (2/5, LOW) — base-case value ~$7.50 vs ~$7.12 today. KEY METRICS: - Consolidated revenue $294.399M; haptic licensing $3.804M - Parent GAAP income $4.876M; reported diluted EPS $0.17 uses a $5.752M adjusted numerator - Equity and derivative gains $13.763M; haptic operating profit $0.306M - Parent cash $167.000M; all parent liabilities $54.375M including written options $22.674M - BNED ownership 32.3%; debt nonrecourse to parent; quoted stake valued separately - HOLD 2/5, Very High uncertainty; base $7.50, scenario weighted $7.35 - Central method range $7–$8; scenario range $5–$10.50 What to watch: Watch parent liquid bridge $147.323 M, written options $22.674 M and haptic EBIT $0.306 M. A conditional entry about $5.63 requires an intact thesis; above $9 prompts a valuation review. Full research packet: https://chargedalpha.com/research/immr-q1-fy2027 Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

  • Thursday · 13 min

    UROY Stock: Profit Surge, New Owners, and a $40M Deadline — Q1 FY2027

    Uranium Royalty Corp. (UROY) Q1 FY2027 — September 16 regular-session close: $4.39. Current economic shares include common and exchangeable claims. Uranium Royalty reported sharply higher earnings while monetizing its remaining physical stockpile. Sweetwater changed the share count, debt and cash priorities, and a $40M bridge must be repaid by January 31, 2027. THE CALL: SELL (2/5, LOW) — base-case value ~$2.25 vs ~$4.39 today. KEY METRICS: - Q1 revenue $51.683M, +112.9% YoY - Parent net income $16.247M; diluted EPS $0.10 - Common plus exchangeable shares 381.067M - Unrestricted cash $54.104M; restricted cash $49.547M - Bridge $40M due January 31, 2027; substantial doubt not alleviated - SELL 2/5; base $2.25; weighted $2.425; scenario range $1–$5 What to watch: Committed funding before January 31, 2027, recurring royalty distributions and per-share value preserved through financing. Full research packet: https://chargedalpha.com/research/uroy-q1-fy2027 Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

  • Thursday · 12 min

    ALMU Stock: The $30M CHIPS Deal Has an Equity Price — Q4 FY2026

    Aeluma, Inc. (ALMU) Q4 FY2026 — The saved preliminary after-hours trade was $11.10 at 19:58:09 EDT on September 16, down 17.35% from the $13.43 regular-session close. Aeluma has cash for development, but its conditional CHIPS proposal involves equity securities equal in value to the award. Commercial demand must still justify the higher spending and ownership claims. THE CALL: SELL (2/5, LOW) — base-case value ~$7.00 vs ~$11.10 today. KEY METRICS: - Q4 revenue $0.582M, down 55.81% YoY - Q4 GAAP net loss $4.013M; EPS −$0.22 - Q4 non-GAAP net loss $2.705M; adjusted EPS −$0.15 - June 30 cash $56.006M; September 11 basic shares 19.265671M - FY2026 computed free cash flow −$3.912M - CHIPS proposal up to $30M; conditional award with equal-value equity - SELL 2/5; base $7; weighted $7.85; range $2–20 What to watch: Quarterly revenue above $1.5M with recurring commercial contribution, disciplined operating cash use and verified funding/ownership terms. Full research packet: https://chargedalpha.com/research/almu-q4-fy2026 Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

  • Thursday · 13 min

    LEN Stock: Land-Light, Cash-Heavy — Q3 FY2026

    Lennar Corporation (LEN) Q3 FY2026 — FMP dated after-hours trade $76.74 at September 16, 2026 23:59:38 UTC, −2.07% versus the $78.36 pre-release regular close. The regular-session −2.14% move preceded earnings. Lennar owns fewer lots and builds homes faster, but cash remains committed to inventory and land deposits. Q3 FY2026 shows why the land-light strategy still needs a cash-conversion recovery. THE CALL: HOLD (3/5, MODERATE) — base-case value ~$75.00 vs ~$76.74 today. KEY METRICS: - Q3 revenue $8.046B, down 8.7% year over year - GAAP EPS $1.19; company adjusted EPS $1.23 - Homebuilding cash $1.150B, down $2.291B since fiscal year-end - Owned inventory increased $1.614B; deposits increased $943.6M since FY2025 end - FY2026 delivery target 80,000–81,000 versus 82,000–83,000 previously - HOLD, 3/5 conviction, $75 base and weighted value, High uncertainty - Central valuation band $65–80; stress scenarios $50–105 What to watch: Watch Q4 deliveries 22,000–23,000 and gross margin 15.5%–16.0%; analyst green checkpoints are homebuilding cash above $2.0B and net debt below $2.5B. A $60 potential entry requires the underlying thesis to remain intact. Full research packet: https://chargedalpha.com/research/len-q3-fy2026 Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

  • September 15 · 13 min

    LAES Stock: The Cash Cushion Shrinks Per Share — H1 2026

    SEALSQ Corp (LAES) H1 2026 — The September 15 intraday quote was $2.26; this is a dated snapshot, not a closing reaction. SEALSQ more than doubled first-half revenue, but operating losses and free-cash burn widened. The cash cushion also looks different when F-share economic rights and the complete share count are included. THE CALL: SELL (3/5, MODERATE) — base-case value ~$1.65 vs ~$2.26 today. KEY METRICS: - H1 revenue $11.151M, up 131.1% YoY - Gross profit $5.408M; gross margin 48.5% - Operating loss $32.162M; consolidated net loss $27.789M - OCF −$23.731M; FCF −$25.249M - Net liquid assets $481.033M before burn/commitments - Model economic shares 231.140922M; net liquid assets/share $2.08 - Mean fair value $1.65; separate probability-weighted value $1.805 What to watch: Commercial post-quantum revenue by year-end, H2 operating cash use at or below $20M, related-party receivables below $14M, and disciplined economic share growth. Full research packet: https://chargedalpha.com/research/laes-h1-2026 Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

  • September 15 · 14 min

    FPS Stock: Record Orders, but Who Funds the Cash Ramp? — Q4 FY2026

    Forgent Power Solutions, Inc. (FPS) Q4 FY2026 — Verified Sep15 07:25:17 CDT early trade $30.6661, +7.07% versus Sep14 close $28.64; regular session and 10:00 CDT results call were pending at the source cutoff. Forgent has record orders and real operating growth. Customer advances fund much of the cash ramp, while the Up-C ownership and tax bridge determine how much value belongs to each economic share. THE CALL: HOLD (3/5, MODERATE) — base-case value ~$29.00 vs ~$30.67 today. KEY METRICS: - Q4 revenue $461.7M, +94.3% YoY - Q4 GAAP EPS $0.21; adjusted EPS $0.25 - Q4 operating cash $73.901M; customer-advance inflow $130.345M - FY2026 computed FCF −$6.824M after all equipment purchases - FY2027 company revenue guide $2.4–2.6B - Model economic diluted interests304.755889M; net face debt$501.023M - Base fair value$29.00; probability-weighted scenario value$29.38 What to watch: Track FY2027 revenue guide $2.4–2.6B, adjusted margins above22%, positive operating cash as advances grow slower than sales, and disciplined capex; recheck economic ownership. Full research packet: https://chargedalpha.com/research/fps-q4-fy2026 Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

  • September 15 · 13 min

    BNTC Stock: $180 Million Cash, But What Does Each Share Own? — FY2026

    Benitec Biopharma Inc. (BNTC) FY2026 — Reference quote $12.08 at September 14 close; no clean post-release reaction quote captured. Benitec has $180 million cash, but prefunded warrants change what each share owns. Equity compensation and uncertain clinical economics drive the valuation. THE CALL: SELL (3/5, MODERATE) — September 2027 twelve-month target ~$6.62 vs ~$12.08 at the September 14, 2026 release-boundary close. KEY METRICS: - FY2026 net loss $45.546M; operating expense $51.192M - Cash equivalents $179.972M at June 30 - SBC $26.410M; OCF cash use $16.518M - Economic shares 49.487M including prefunded warrants; computed cash/share $3.64 - 12-month target $6.62; probability-weighted scenario value $7.702; Very High uncertainty What to watch: Clear pivotal requirements, durable follow-up, a reconciled economic cap table and no renewed material compensation-accounting corrections. Full research packet: https://chargedalpha.com/research/bntc-fy2026 Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

  • September 15 · 12 min

    HITI Stock: Germany Scales, but Where Is the Cash? — Q3 FY2026

    High Tide Inc. (HITI) Q3 FY2026 — Reference price US$2.63 at the September 14 regular close; no completed post-release reaction is claimed. Germany is lifting High Tide’s operating earnings, but derivative gains dominate its reported profit. Follow the ownership, reinvestment and financing bridge to see how much becomes shareholder cash. THE CALL: HOLD (3/5, MODERATE) — base-case value ~$2.60 vs ~$2.63 today. KEY METRICS: - Revenue C$198.818M, +32.82% YoY - Operating income C$8.710M, +132.95% YoY - Reported net income C$12.748M includes net C$10.502M fair-value benefit - Company adjusted net income C$2.246M; consolidated - Company FCF C$7.017M; all-capex after-lease cash proxy C$5.611M - Base fair value US$2.60; probability-weighted scenario value US$2.486 - Remexian ownership 51%; current common shares 88.897395M What to watch: Sustain at least C$4M quarterly German adjusted EBITDA, 5% legacy-segment revenue growth and C$6M full-capex cash with stable working capital; verify control remediation. Full research packet: https://chargedalpha.com/research/hiti-q3-fy2026 Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

  • September 14 · 14 min

    ABAT Stock: Can Customers Still Place Orders? — FY2026

    American Battery Technology Company (ABAT) FY2026 — September 11 close $2.47 precedes the September 14 audited annual filing. August 20 Q4 figures were preliminary; no completed post-filing session is attributed here. Can a recycling company grow if its customers cannot buy? ABAT’s audited FY2026 report shows better factory economics, substantial stock compensation and a new customer-access constraint. We trace sales and financing through to common-share value. THE CALL: SELL (3/5, MEDIUM) — base-case value ~$1.25 vs ~$2.47 today. KEY METRICS: - Audited FY2026 revenue $21.742M, up 406.8%; net loss $73.379M - Derived Q4 revenue $8.233M and gross profit $1.289M; annual less nine months - Annual stock compensation $46.481M, 214% of revenue - June unrestricted cash $49.519M; operating + investing cash use $37.765M - Black mass supplies majority of revenue; substantially all current black-mass buyers are abroad - Exception requested to domestic allocation requirement; approval not verified - Primary DCF $1.23; terminal-sales / funding-reserved-book checks $1.43 / $1.57; $1.25 anchor - SELL, $1.25 base, 3/5 conviction, Very High uncertainty; scenario-weighted $1.48 What to watch: Conditional entry near $0.81 with a viable customer route and financing discipline. Analyst review November 30, 2026; watch GAAP gross margin above 15%, collected revenue, quarterly cash use above $12M without funded progress, or >10% additional common dilution without per-share benefit. These are research thresholds, not guidance. Full research packet: https://chargedalpha.com/research/abat-fy2026 Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

  • September 14 · 14 min

    IMPP Stock: Who Owns the Cash Windfall? — Q2 2026

    Imperial Petroleum Inc. (IMPP) Q2 2026 — September 11 regular close $5.79. Company release September 10; SEC acceptance September 11. June financials and August shares are labeled separately. Imperial Petroleum earned more, but who owns the cash windfall? We trace liquidity through vessel commitments, preferred priority and warrants to common-share value. THE CALL: HOLD (2/5, LOW) — base-case value ~$7.00 vs ~$5.79 today. KEY METRICS: - Q2 revenue $87.073M, up 139.5%; operating profit $33.398M - Q2 net income $34.759M; basic / diluted EPS $0.75 / $0.70 - June cash + deposits $245.231M; related-party payable $35.152M - August common shares 45.621M imply $264.148M market value at $5.79 - Series A priority $19.897M; F/G warrant strike $6.30 - Analyst routes $7.19 / $6.68 / $6.73; shared 65% existing-equity factor - Base $7; scenario-weighted $6.45; HOLD 2/5, Very High uncertainty What to watch: Conditional entry $5.25 if fleet economics, liquidity and ownership remain sound. Analyst adverse tests: recurring quarterly EBIT below $12M; liquidity below $100M without adequate returns; common shares above 50M without commensurate value. Full research packet: https://chargedalpha.com/research/impp-q2-2026 Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

  • September 11 · 12 min

    USAU Stock: Who Pays to Build CK Gold? — Q1 FY2027

    U.S. Gold Corp. (USAU) Q1 FY2027 — September 11 regular close $15.20, +0.86% from $15.07. The daily move includes trading before and after the filing; it is not an isolated filing reaction. A permitted mine still needs someone to pay for it. We follow U.S. Gold’s Q1 FY2027 loss, cash use, CK Gold financing requirements and potential dilution from project NPV to common-share value. THE CALL: HOLD (2/5, LOW) — base-case value ~$14.00 vs ~$15.20 today. KEY METRICS: - No revenue; quarterly net loss $4.601M versus $2.077M - Operating cash use $3.541M, up 6.8%; prior warrant gain complicates loss comparison - July cash $27.115M versus $422.386M detailed initial capital estimate - Industrial Siting Permit extended through December 2027; financial capacity required for restart - Study after-tax NPV5 $632.259M already includes initial construction spending - Analyst annual DCF / risked NAV / financing checks: $13.43 / $16.27 / $12.68 - Base fair value $14; central method range $12.50–16.50; scenario-weighted value $13.30 - HOLD, 2/5 conviction, Very High uncertainty; conditional entry $10.50 What to watch: Conditional entry $10.50 only with credible funding, cost control and the permit pathway intact. Review funding by December 31, 2026; watch costs above about $486M without an offset, quarterly cash use above $5M without progress, or cash below $10M while unfunded. These are analyst thresholds. Full research packet: https://chargedalpha.com/research/usau-q1-fy2027 Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

  • September 11 · 12 min

    FIZZ Stock: Pricing Held Sales. Can Profit Recover? — Q1 FY2027

    National Beverage Corp. (FIZZ) Q1 FY2027 — September 10 regular close: $30.91, before the filing. No verified executed post-print reaction price. Pricing holds sales as case volume falls and aluminum squeezes profit. We test the recovery against cash quality, concentrated control and three valuation routes. THE CALL: HOLD (3/5, MODERATE) — base-case value ~$28.50 vs ~$30.91 today. KEY METRICS: - Revenue $330.662M; price/case +7.1%, volume −6.4% - Gross margin 35.0% vs 38.0%; aluminum estimated 600bps pressure within net 300bps decline - Operating profit $58.480M; net income $47.004M; diluted EPS $0.50 - CFO $64.850M and FCF $61.779M include working-capital and tax timing - Cash $107.098M; no funded borrowing; 94M gross share modeling assumption - Cash added to value $52.581M after $50M reserve and $4.517M existing tax payable - DCF $25.62 / earnings $31.47 / revenue $30.39; 50/30/20 blend rounds to $28.50 - Bear/base/bull $20/$28.50/$43; 30/50/20 probabilities give $28.85 What to watch: Conditional entry $21.38, approximately 25% below $28.50 base, if demand, margins and liquidity hold. Review by December 15, 2026 (analyst deadline): case decline better than 3%, gross margin at least 36%, cash at least $75M. Adverse: volume below −8%, margin below 33.5%, unexplained cash below $50M, funded debt above $25M or gross shares above 95M. Full research packet: https://chargedalpha.com/research/fizz-q1-fy2027 Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

  • September 11 · 14 min

    UNFI Stock: Profit Recovered. Why Is the Cash Guide Lower? — Q4 FY2026

    United Natural Foods, Inc. (UNFI) Q4 FY2026 — September 10 close $44.11: +0.4% from the pre-print close after an initial +2.3% release-day gain. Operating profit recovered, but next year’s cash-flow midpoint is lower. We test distribution efficiency, recurring adjustments, investment and shareholder claims. THE CALL: HOLD (2/5, LOW) — base-case value ~$49 vs ~$44.11 today. KEY METRICS: - Q4 revenue $7.642B; GAAP operating profit $69M; net income $35M; diluted EPS $0.57 - Adjusted EBITDA $172M; adjusted EPS $0.69; cyber benefit removed $3M Q4 / $21M FY - FY2026 FCF $323M; FY2027 guide $275–325M; capital/cloud plan about $300M - Net debt $1.539B includes finance leases; operating leases $1.459B disclosed separately - Model shares 62.9M diluted weighted average; published FCF adds back SBC - EPS / EV-EBITDA / equity FCF routes: $45.50 / $53.55 / $47.69; 30/30/40 blend → $49 - Illustrative $61M SBC cash charge: $38.00 cash route / $44.91 blend; base unchanged - Scenarios $32/$49/$71 at 30/50/20 → $48.30 weighted; central band $44–54 What to watch: Conditional entry $39.20, 20% below $49 base, if cash, leverage and service hold. Expected December update: watch FCF guide floor below $275M, leverage above 2.5x, sales worse than −3%, or quarterly transformation above $15M. Above $54 without improved fundamentals prompts valuation review. Full research packet: https://chargedalpha.com/research/unfi-q4-fy2026 Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

  • September 11 · 13 min

    DBI Stock: Who Keeps the Tariff Windfall? — Q2 FY2026

    Designer Brands Inc. (DBI) Q2 FY2026 — DBI closed at $5.99 on September 10, up 14.75% that day; exact release clock and causal attribution not independently established. Designer Brands has a genuine operating recovery and a complicated tariff windfall. We reconcile the Investor financing, retained refund inside adjusted profit, Topo minority rights, finance leases and potential awards to value the common residual. THE CALL: SELL (3/5, MODERATE) — base-case value ~$3.50 vs ~$5.99 today. KEY METRICS: - Revenue $730.631M, −1.2%; Retail comps −2.6% - Gross margin 50.0% reported / 47.9% issuer adjusted / 45.14% fully ex-refund - Full COGS recovery $35.536M; issuer removes only $15.336M, retaining $20.200M - Full ex-refund Q2 EBIT $19.187M vs restated prior $26.143M; H1 $38.057M - Investor: $18.3M claims sold for $2.2M; Q2 remittance $18.3M includes $16.097M interest - Adjusted NI $19.228M adds back $2.860M minority attribution; not all public-common profit - H1 CFO $48.236M; cash capex $22.251M; FCF $25.985M includes rounded $20.7M company CFO refund benefit - Face debt $425.973M; inferred finance leases $29.462M; cash $51.591M - Analyst Topo claim $15M and cash reserve $20M; net modeled enterprise claims $438.844M - 66M deliberately gross potential-share assumption; overlap and vesting caveats, not GAAP diluted shares - DCF $4.366 / economic NOPAT $3.403 / revenue EV $1.981; 50/30/20 blend $3.59996 rounded $3.50 - Bear/base/bull $1/$3.50/$8; weights 30%/50%/20% give $3.65; conditional entry $2.45 What to watch: Review the next Q3 filing by December 15, 2026, an analytical deadline rather than a confirmed reporting date. Positive tests: Retail comparable sales at least 0%, fully ex-refund gross margin at least 45.5%, and underlying EBIT at least $35M. Adverse tests: comps below −4%, margin below 44%, EBIT below $20M, unexplained cash below $35M, funded face debt plus finance leases above $475M, or potential common claims above 69M. Conditional entry $2.45 is 30% below base, with funding, duty resolution and the retail recovery intact. Full research packet: https://chargedalpha.com/research/dbi-q2-fy2026 Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.

Showing 1–20 of 193 episodes